Latest Period
Q2 2026
Security Snapshot
BioNexus Gene Lab Corp - Common Stock, no par value (BGLC) Institutional Ownership
CUSIP: 090628306
13F Institutional Holders and Ownership History from Q2 2025 to Q2 2026
Institutions Reporting
3
Shares (Excl. Options)
14,385
Price
$1.95
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, no par value
- Symbol
- BGLC on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 14,385
- Total 13F value
- $27,199
- Portfolio coverage rank
- 0%
- Share change
- +14,153
- Value change
- +$26,746
- Number of holders
- 3
- Shares outstanding
- 2,945,296
- SEC-reported price per share
- $1.33
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- BGLC - BioNexus Gene Lab Corp - Common Stock, no par value is tracked under CUSIP 090628306.
- 3 institutions reported positions in Q2 2026.
- 1 significant owner is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 2 to 3 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $497 to $27,199.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 3 institutions filings for Q2 2026.
Security key
090628306
Latest holder period
Q2 2026
13F holders
3
13D/G owners
1
CIK / CUSIP context first
Open Q2 2026 holders
BGLC full holder history
BioNexus Gene Lab Corp SEC filings
BioNexus Gene Lab Corp company facts
BioNexus Gene Lab Corp insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 090628306:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
1
Security
BGLC
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Tan Lee Su-Leng | 12% | $677,418 | 338,709 | Tan Lee Su-Leng | 13 Aug 2026 |
As of 30 Jun 2026, 3 institutional investors reported holding 14,385 shares of BioNexus Gene Lab Corp - Common Stock, no par value (BGLC). This represents 0.49% of the company’s total 2,945,296 outstanding shares.
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
5
Latest
Q2 2026
Rows shown
1-5 of 5